What You Should Know: - Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. IBF and Peregrine Ventures led the round, with participation from aMoon Fund and other existing investors. - The funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of
Read More
Biotech Startup Akrevia Therapeutics Lands $30M to Develop Next-Gen Cancer Immunotherapies
Akrevia Therapeutic, a Cambridge, MA-based biotech startup focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics has raised $30 million in funding led by F-Prime Capital Partners and Atlas Venture. The funding will be used to accelerate Akrevia's pipeline and proprietary Aklusion® platform, which allows therapeutic antibodies, cytokines and chemokines to be specifically activated in the tumor microenvironment and tailored with precisely optimized pharmacologic
Read More
